Sacituzumab Tirumotecan API is an investigational TROP2-directed antibody-drug conjugate (ADC) being developed for the treatment of advanced and metastatic solid tumors. The compound is also identified as Sac-TMT, MK-2870 and SKB264. Unlike a conventional chemical active pharmaceutical ingredient, sacituzumab tirumotecan is a complex biological conjugate consisting of a humanized anti-TROP2 monoclonal antibody linked to a topoisomerase-I inhibitor payload.
The U.S. National Library of Medicine's Global Substance Registration System identifies Sacituzumab Tirumotecan under CAS 2768350-77-0, FDA UNII 3DV5TD1VL3, USAN NO-68, and INN 12801. GSRS estimates an average molecular weight of approximately 146,000 Da and provides an estimated molecular formula of C6496H9972N1702O2016S42. Because this is an ADC with molecular heterogeneity, these values should be treated as estimated/average descriptors rather than the type of fixed molecular formula normally used for a small-molecule API.
Sacituzumab tirumotecan is a TROP2-targeted ADC. The antibody component recognizes trophoblast cell-surface antigen 2 (TROP2), which is expressed in a broad range of epithelial cancers. The antibody is covalently linked to KL610023, a topoisomerase-I inhibitor payload, through an ADC linker system. Current clinical-trial documentation describes sacituzumab tirumotecan as a humanized anti-TROP2 monoclonal antibody of the IgG1 class covalently linked to the cytotoxic payload KL610023.
The ADC design enables targeted delivery of a potent cytotoxic compound to TROP2-expressing tumor cells. Because the product is a biological conjugate, its critical quality attributes include antibody identity, conjugation characteristics, payload loading, aggregation, fragmentation, charge variants and biological activity.
Sacituzumab tirumotecan is currently an investigational oncology therapeutic rather than an established commercially approved API. Clinical development is evaluating the ADC across multiple advanced and metastatic solid tumors.
Active and recent clinical programs include investigations in:
The NCI currently lists multiple active clinical trials involving sacituzumab tirumotecan, while ClinicalTrials.gov identifies MK-2870/Sac-TMT as an investigational biological intervention.
Sacituzumab tirumotecan is designed to bind TROP2 on tumor cells. Following binding, the ADC is internalized into the target cell, where the linker/payload system facilitates delivery of the cytotoxic topoisomerase-I inhibitor.
The released payload interferes with the normal activity of topoisomerase I, an enzyme required for DNA replication and repair. Inhibition of topoisomerase I results in accumulation of DNA damage and can ultimately induce tumor-cell death.
This targeted ADC approach combines the molecular recognition capability of a monoclonal antibody with the cytotoxic activity of a topoisomerase-I inhibitor.
As an investigational ADC, Sacituzumab Tirumotecan requires a specialized biologics and ADC analytical-control strategy.
Important quality attributes may include:
Because the product is heterogeneous by nature, an average molecular weight or estimated formula should not be interpreted as a conventional small-molecule specification. GSRS itself identifies the molecular weight and formula as estimated.
Sacituzumab tirumotecan requires specialized ADC manufacturing involving production of the antibody component, preparation of the chemical linker/payload system, controlled conjugation and subsequent purification.
The manufacturing process must control the antibody's structural integrity and the extent and distribution of payload conjugation. Downstream purification is required to control aggregates, unconjugated components and other product- and process-related impurities.
Because Sacituzumab Tirumotecan remains an investigational product, commercial pharmaceutical manufacturing specifications should be based on the applicable development-stage quality system and regulatory dossier rather than an assumed pharmacopoeial monograph.
Sacituzumab tirumotecan is a complex biological ADC.
Key currently available identifiers include:
These values are taken from the NIH GSRS record; the formula and molecular weight are explicitly designated as estimated.
Because Sacituzumab Tirumotecan is an investigational biological ADC, packaging and storage should follow the validated development specification and stability program.
Published research-product information reports specialized frozen handling, but this should not be presented as a universal regulatory API storage specification. Storage conditions can differ according to the development stage, formulation and manufacturer-specific stability data.
A qualified Sacituzumab Tirumotecan development/manufacturing organization may provide applicable technical documentation, including:
Sacituzumab tirumotecan requires specialized capabilities in biologics, ADC conjugation and analytical characterization. A qualified development or manufacturing partner should therefore have appropriate expertise in recombinant antibody production, controlled conjugation, purification, payload characterization and biological potency testing.
For this product, conventional small-molecule API specifications such as a generic 98–102% assay should not be applied. Quality should instead be established through ADC-specific critical quality attributes and validated analytical methods.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |
| Water Content | NMT 0.5% |